The antibody was conjugated with Alexa Fluor® 647 under optimal conditions, and is at >85% purity. The solution is free of unconjugated Alexa Fluor® 647.
Storage & Handling:
The antibody solution should be stored undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining, the suggested use of this reagent is 5 µl per million cells or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
* Alexa Fluor® 647 has a maximum emission of 668 nm when it is excited at 633nm / 635nm. ** Alexa Fluor® is a registered trademark of Molecular Probes, Inc. Alexa Fluor® dye antibody conjugates are sold under license from Molecular Probes, Inc. for research use only, except for use in combination with microarrays and high content screening, and are covered by pending and issued patents.
1. Valentin, H., et al. 1992. Transplantation. 54: 97
Human peripheral blood lymphocytes stained with 097 Alexa Fluor® 647
Description:
CD52, also known as Cambridge pathology antigen 1 (CAMPATH-1), is a 25-29 kD glycoprotein containing a large N-linked carbohydrate moiety. The actual molecule of CD52 is only 8-9 kD. It is expressed in the male reproductive tract and on virtually all lymphocytes (T and B cells), as well as macrophages/monocytes, eosinophils, and red cells. CD52 is thought to play a role in carrying and orienting carbohydrates. CD52 is a potent target for complement-mediated lysis and antibody-mediated cellular cytotoxicity and has been used as a depletion target for chronic lymphocytic leukemia (CLL)/lymphoma and immunosuppression.
Other Names:
Cambridge pathology antigen 1 (CAMPATH-1), epididymal secretory protein 1
Male reproductive tract (epididymis, seminal vesicle), T cells, B cells, macrophage/monocyte, eosinophil, erythrocytes, malignant lymphocytes
Function:
Thought to play a role in carrying and orienting carbohydrates. Target for complement-mediated lysis and antibody-dependent cellular cytotoxicity, used as a depletion target for chronic lymphocytic leukemia/lymphoma therapy and immunosuppression.
Antigen References:
1. Leukocyte Typing VI. Kishimoto, T., et al. (Eds.), Garland Publishing Inc. (1997) 2. Xia, M.-Q., et al., 1991. Eur. J. Immunol. 21:1677. 3. Kirchhoff, C. et al., 1993. Mol. Reprod. Dev. 34:8. 4. Xia, M.Q., et al., 1993. Biochem. J. 293:633.
*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering/). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.
